Health at a Glance Report highlights public value of generic, biosimilar and value added medicines

26 November 2018

The European Commission and OECD – Health at a Glance: […]

Driving local excellence, delivering European results

5 November 2018

Medicines for Europe is glad to announce the occasion of […]

Risk that European Council will “neuter” SPC manufacturing waiver and give foreign (non-EU) manufacturers strong advantage over EU-based manufacturers

11 October 2018

There is a concrete risk that disproportionate influence on the […]

CJEU decision on Gilead’s SPC on Truvada® leads to successful clarification in English court

20 September 2018

An English Court has determined that the contested supplementary protection […]

SPC manufacturing waiver moves a step closer as influential European Parliament ENVI Committee supports reform

17 September 2018

Medicines for Europe welcomes the European Parliament’s Committee on Environment, […]

Medicines for Europe members publish disclosure of Transfers of Value to the healthcare community

22 June 2018

Medicines for Europe is committed to bringing accessible, high quality […]

Access, sustainability and manufacturing competitiveness highlighted at global generic, biosimilar and value added pharmaceutical conference in Budapest

14 June 2018

The joint 24th Medicines for Europe and 21st IGBA Annual […]

IGBA Joins ICH Management Committee and Welcomes the Positive Vote of the General Assembly

7 June 2018

Comprehensive SPC manufacturing waiver key for patient access to medicines, jobs and growth in Europe

28 May 2018

Medicines for Europe commends the European Commission for proposing an […]

EU Semester Country Specific Recommendations: Improve patient access to medicine and ensure healthcare sustainability

24 May 2018

The European Semester Country Specific Recommendations show that healthcare systems […]